Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

COVID-19 Pandemic Leads Big Drugmakers to Hit Pause on Clinical Trials

Reuters Staff  |  March 25, 2020

(Reuters)—U.S. drugmakers Eli Lilly and Co. and Bristol Myers Squibb said they are delaying the start of new clinical trials in part to free up doctors and healthcare facilities to deal with the surge in patients infected with the new coronavirus.

Lilly and Bristol are the biggest drugmakers yet to announce clinical trial delays in the face of the pandemic that has killed over 16,000 people worldwide, after several small biotech companies said last week that they would be pulling back on drug studies.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The moves are not related to clinical trials testing drugs or vaccines that could be used to treat or prevent COVID-19, the respiratory illness caused by the virus.

The U.S. Food and Drug Administration last week urged switching to virtual patient visits instead of in-person monitoring when conducting clinical studies as it anticipated the outbreak would disrupt them.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Pfizer Inc, Merck & Co, AbbVie Inc, and Johnson & Johnson were not immediately available for comment on their trials policies.

Delaying clinical trials could hurt future revenue for pharmaceutical companies as it lengthens the time it takes for drugs to receive approval and reach the market. It could also hurt patients by limiting their access to experimental treatments being studied.

Lilly said the move would delay the timeline for ongoing late-stage studies of its experimental gastrointestinal disease treatment mirikizumab.

The Indianapolis-based drugmaker said there will not be any delay in other ongoing late-stage trials.

It added that it would analyze ongoing trials on a study-by-study basis, as discontinuing them would disrupt the treatment course for patients. But it plans to continue most trials where patients are already enrolled.

Lilly said it does not anticipate any change to its full-year financial forecast as a result of the coronavirus outbreak.

Bristol posted a message to clinical trial investigators on its website on Friday, saying it will put off beginning new clinical trials for at least three weeks because of the impact of the rapidly spreading coronavirus pandemic.

The New York-based drugmaker said it will not initiate any new sites for clinical trials until April 13, noting that the timeframe of the halt could extend further.

It also said studies involving healthy volunteers should be put on hold if they are at a natural break point until at least April 13.

Bristol did not say how many trials or which drugs in development might be affected.

Financial Cost to Hospitals
Conducting clinical trials is a good source of revenue for non-profit and academic hospitals, but are not as significant for for-profit hospital companies, Jefferies Analyst Brian Tanquilut said.

Page: 1 2 | Single Page
Share: 

Filed under:Drug UpdatesResearch Rheum Tagged with:clinical trialscoronavirusCOVID-19drugmakersResearch

Related Articles

    4 Steps to a More Efficient Healthcare Revenue Cycle in a Physician Practice

    November 16, 2016

    As the year draws to a close, it is vital to pay close attention to your practice’s revenue cycle to maintain an operational and financially healthy business. Operational aspects should be a top priority, with careful monitoring as they relate to efficiency in receivables and denials management. Healthcare revenue cycle management is the strategy that…

    Enemy at the Gates: The Emerging Threat of COVID-19

    March 23, 2020

    On Dec. 30, 2019, an ophthalmologist named Li Wenliang notified his colleagues about an illness that was reminiscent of severe acute respiratory syndrome (SARS) in a city in the Hubei province of China called Wuhan. As an ophthalmologist, this was not directly relevant to his practice; he merely wanted to warn colleagues that they might…

    Revenue Cycle Management in Physician Practice Improves with Staff Communication, Training

    November 17, 2015

    One month has passed since the U.S. healthcare system overcame a historical milestone with the conversion from billing ICD-9-CM to ICD-10-CM. Although the transition to ICD-10 had a major impact on coding operations, its far-reaching tentacles go beyond coding alone and are deeply rooted in the entire revenue cycle. There is room to criticize the…

    Mitigate Risk and Increase Success of Lupus Clinical Trials

    August 1, 2010

    Design strategies from a Lupus Research Institute conference

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences